Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

MLL1-Induced Oncogenic Reprogramming Drives EZH2 Inhibitor Resistance

DOI: 10.1158/2159-8290.CD-RW2018-159 Published November 2018
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: Tumor-intrinsic MLL1 drives transcriptional reprogramming in response to EZH2 inhibition.

  • Mechanism: MLL1 interacts with the p300/CBP complex to drive reciprocal H3K27ac gain at sites of H3K27me loss.

  • Impact: MLL1 status may inform precision therapy for patients with EZH2-overexpressing tumors.

Overexpression or gain-of-function mutations in EZH2, the enzymatic subunit of the histone methyltransferase polycomb repressive complex 2 (PRC2), promote oncogenesis in solid tumors and hematologic malignancies, respectively. Given that mutant EZH2 has been shown to drive H3K27 methylation (H3K27me)–dependent growth, Huang, Yan, Zhang, Wang, and colleagues epigenetically profiled a panel of EZH2-overexpressing blood and solid cancer cell lines with varying sensitivities to EZH2 inhibition (EZH2i). EZH2i reduced H3K27me in both hematologic and solid-cancer cell lines, inhibited growth of hematologic cancer cell lines, and induced H3K27 acetylation (H3K27ac) in EZH2i-resistant cell lines. Knockdown of p300 or CBP, both of which comprise the complex that catalyzes H3K27ac, sensitized EZH2i-resistant cell lines that express MLL1, which facilitates binding of p300/CBP to target sites, to EZH2 inhibition. Consistent with these findings, MLL1 expression was correlated with increased H3K27ac in EZH2i-resistant cell lines, and ablation of MLL1 resulted in decreased formation of p300/CBP complexes and H3K27ac. Integrated chromatin immunoprecipitation sequencing, RNA sequencing, and proteomic analysis showed that EZH2i treatment induced transcriptional reprogramming via a H3K27me-to-H3K27ac switch in EZH2i resistant cell lines. Treatment with a BRD4 inhibitor, which targets H3K27ac, sensitized EZH2i-resistant cells to EZH2 inhibition in vitro, and combined inhibition of BRD4 and EZH2 reduced growth of a subset of patient-derived xenografts (PDX) in vivo. Proteomic analyses revealed that PDXs that did not respond to combined inhibition of BRD4 and EZH2 exhibited increased MAPK signaling due to BRD4i-mediated inactivation of ERK1 and subsequent activation of ERK2. Combined targeting of EZH2, BRD4, and ERK1/2 suppressed the growth of liver and pancreatic cancer xenografts without significant toxicity in vivo. These results show that resistance to EZH2 inhibition is driven by MLL1-mediated transcriptional reprogramming in patients with EZH2-overexpressing tumors, who potentially could be stratified by MLL1 status for EZH2i either as a monotherapy or in combination with therapies targeting H3K27ac and/or MAPK signaling.

Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell 2018;175:186–99.e19.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2018 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 8 (11)
November 2018
Volume 8, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MLL1-Induced Oncogenic Reprogramming Drives EZH2 Inhibitor Resistance
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MLL1-Induced Oncogenic Reprogramming Drives EZH2 Inhibitor Resistance
Cancer Discov November 1 2018 (8) (11) 1344; DOI: 10.1158/2159-8290.CD-RW2018-159

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MLL1-Induced Oncogenic Reprogramming Drives EZH2 Inhibitor Resistance
Cancer Discov November 1 2018 (8) (11) 1344; DOI: 10.1158/2159-8290.CD-RW2018-159
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • In Vivo CRISPR Screen Identifies FLI1 as Regulator of Effector T Cells
  • Trial Supports Combination Treatment and New Target for Multiple Myeloma
  • Mitochondrial DNA Damage Triggers an IFN-Mediated Immune Response
Show more Research Watch

Epigenetics

  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • H1 Loss Increases Accessibility of Stemness Genes to Drive Lymphoma
Show more Epigenetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement